RVMD Legal Chief Retains 54,000 Shares After Planned Stock Sale

(Moderate)

(Neutral)

Form Type

Rhea-AI Filing Summary

Revolution Medicines (RVMD) General Counsel Jeff Cislini reported a sale of 1,912 shares of common stock on June 20, 2025, at a weighted average price of $39.61 per share (range: $39.26-$40.05). The transaction was executed under a pre-established 10b5-1 trading plan adopted on March 13, 2025.

Following the transaction, Cislini retains beneficial ownership of 54,093 shares, including 49,054 restricted stock units. The sale was reported through Form 4 filed on June 28, 2025, and was executed in compliance with SEC regulations. The transaction was filed by Cislini's attorney-in-fact, Jack Anders.

Insider Trade Summary

Net Seller: 1,912 shares

Net Sell 1 txn

Insider Cislini Jeff

Role General Counsel

Sold 1,912 shs ($76K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,912	$39.6108	$76K

Holdings After Transaction: Common Stock — 54,093 shares (Direct)

Footnotes (3)

F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
F2. This transaction was executed in multiple trades in prices ranging from $39.26 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. Includes 49,054 restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/23/2025 - 04:07 PM

FAQ

How many shares of RVMD stock did General Counsel Jeff Cislini sell on June 20, 2025?

Jeff Cislini sold 1,912 shares of RVMD common stock on June 20, 2025, at a weighted average price of $39.6108 per share.

What was the price range of RVMD shares sold in the insider transaction on June 20, 2025?

The shares were sold in multiple trades with prices ranging from $39.26 to $40.05 per share, with a weighted average sale price of $39.6108.

How many RVMD shares does Jeff Cislini own after the June 20, 2025 transaction?

Following the reported transaction, Jeff Cislini beneficially owns 54,093 shares, which includes 49,054 restricted stock units (RSUs).

Was RVMD General Counsel's stock sale part of a pre-planned trading arrangement?

Yes, the transaction was made pursuant to a Rule 10b5-1 trading plan that was adopted by Jeff Cislini on March 13, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		S⁽¹⁾		1,912	D	$39.6108⁽²⁾	54,093⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.

2. This transaction was executed in multiple trades in prices ranging from $39.26 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 49,054 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR